Publications by authors named "Maryam Hanafiah"
Aims: Amodiaquine is a 4-aminoquinoline used extensively for the treatment and prevention of malaria. Orally administered amodiaquine is largely converted to the active metabolite desethylamodiaquine. Amodiaquine can cause bradycardia, hypotension, and electrocardiograph QT interval prolongation, but the relationship of these changes to drug concentrations is not well characterized.
View Article and Find Full Text PDFArticle Synopsis
- * A meta-analysis involving 2,681 patients from various clinical trials found that while amodiaquine prolongs the QT interval, it does so less than chloroquine and piperaquine but more than lumefantrine and pyronaridine.
- * In patients aged 12 and older, amodiaquine was linked to a significant decrease in heart rate compared to other treatments, suggesting a greater risk of bradycardia compared to some alternative antimalarial medications.